

# Connie Marras

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6815322/publications.pdf>

Version: 2024-02-01

165  
papers

7,746  
citations

57758

44  
h-index

60623

81  
g-index

168  
all docs

168  
docs citations

168  
times ranked

8536  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of the Ontario Neurodegenerative Disease Research Initiative cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, 226-243.	0.8	15
2	Demographic Influences on the Relationship Between Fatigue and Quality of Life in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 76-81.	1.5	3
3	Surveying Global Availability of Parkinson's Disease Treatment. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1023-1034.	2.8	2
4	Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial. <i>Movement Disorders</i> , 2022, , .	3.9	5
5	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	4.6	4
6	Level I <sup>PD</sup>MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	1.5	11
7	Small and Large Magnetic Resonance Imagingâ€“Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	3.9	11
8	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force â€“ An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.	3.9	49
9	Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiative. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.7	3
10	Epidemiological Evidence for an Immune Component of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, S29-S43.	2.8	3
11	Using artificial intelligence to identify anti-hypertensives as possible disease modifying agents in Parkinson's disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 201-209.	1.9	11
12	Survival and Health Care Use After Deep Brain Stimulation for Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2021, 48, 372-382.	0.5	4
13	Genotypeâ€“Phenotype Relations for Isolated Dystonia Genes: <sup>MDSGene</sup> Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1086-1103.	3.9	74
14	Triggers and alleviating factors for fatigue in Parkinson's disease. <i>PLoS ONE</i> , 2021, 16, e0245285.	2.5	9
15	Infection and Risk of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 31-43.	2.8	54
16	Knowledge, Responsibilities, and Peer Advice From Care Partners of Patients With Parkinson Disease Psychosis. <i>Frontiers in Neurology</i> , 2021, 12, 633645.	2.4	4
17	Use of Figurative Language by People With Parkinson Disease to Describe â€œOff-Periods. <i>Neurology: Clinical Practice</i> , 2021, 11, e462-e471.	1.6	2
18	The experience of care partners of patients with Parkinson's disease psychosis. <i>PLoS ONE</i> , 2021, 16, e0248968.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. <i>Movement Disorders</i> , 2021, 36, 1499-1510.	3.9	22
20	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	2.8	56
21	Current Knowledge on the Evolution of Care Partner Burden, Needs, and Coping in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 510-520.	1.5	11
22	Gene-Environment Interactions in Progressive Supranuclear Palsy. <i>Frontiers in Neurology</i> , 2021, 12, 664796.	2.4	1
23	Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2021, 11, 74.	2.1	39
24	Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients with Early Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1979-1983.	3.9	0
25	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	5.3	30
26	The Experience of OFF Periods in Parkinson's Disease: Descriptions, Triggers, and Alleviating Factors. <i>Journal of Patient-centered Research and Reviews</i> , 2021, 8, 232-238.	0.9	2
27	Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2419-2425.	3.9	11
28	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021, 31, 729-736.	2.5	2
29	Genotype-Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review. <i>Movement Disorders</i> , 2021, 36, 2468-2480.	3.9	35
30	Clinical and Economic Outcomes Associated with Dysphagia in Hospitalized Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1965-1971.	2.8	5
31	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	3.1	8
32	Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2021, 4, 100094.	0.9	18
33	Impact of Off Periods on Persons With Parkinson Disease and Care Partners. <i>Neurology: Clinical Practice</i> , 2021, 11, e232-e238.	1.6	3
34	Small molecule inhibitors of $\alpha$ -synuclein oligomers identified by targeting early dopamine-mediated motor impairment in <i>C. elegans</i> . <i>Molecular Neurodegeneration</i> , 2021, 16, 77.	10.8	13
35	Understanding the Links Between Cardiovascular Disease and Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 55-74.	3.9	71
36	Experience and Impact of OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners. <i>Journal of Parkinson's Disease</i> , 2020, 10, 315-324.	2.8	6

#	ARTICLE	IF	CITATIONS
37	Therapy of Parkinson's Disease Subtypes. <i>Neurotherapeutics</i> , 2020, 17, 1366-1377.	4.4	42
38	Survival in Restless Legs Syndrome: An 11-Year Surveillance, Community-Based Population Study. <i>Neuroepidemiology</i> , 2020, 54, 375-382.	2.3	3
39	Clinical Follow-up of Parkinson's Disease With Newly Prescribed Quetiapine. <i>Movement Disorders</i> , 2020, 35, 1690-1692.	3.9	0
40	Parkinson disease with mild cognitive impairment: Domain-specific cognitive complaints predict dementia. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 585-596.	2.1	9
41	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 127-132.	2.2	10
42	<i>Helicobacter pylori</i> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020, 35, 2250-2260.	3.9	45
43	The Impact of COVID-19 on Access to Parkinson's Disease Medication. <i>Movement Disorders</i> , 2020, 35, 2129-2133.	3.9	40
44	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinson's Disease</i> , 2020, 10, 665-675.	2.8	25
45	Variations in hospitalization rates across Parkinson's Foundation Centers of Excellence. <i>Parkinsonism and Related Disorders</i> , 2020, 81, 123-128.	2.2	9
46	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
47	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.	3.9	4
48	Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study. <i>Movement Disorders</i> , 2020, 35, 1275-1277.	3.9	2
49	Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 864-872.	1.9	22
50	Parkinson's Disease, <i>NOTCH3</i> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	3.9	18
51	Huntington's Disease and Hypertension: Sorting Out Mixed Messages. <i>Movement Disorders</i> , 2020, 35, 915-917.	3.9	0
52	Understanding the Lexicon of Fatigue in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1185-1193.	2.8	4
53	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinson's Disease</i> , 2020, 10, 677-691.	2.8	15
54	Progressive Supranuclear Palsy and Statin Use. <i>Movement Disorders</i> , 2020, 35, 1253-1257.	3.9	2

#	ARTICLE	IF	CITATIONS
55	Disparities in Deep Brain Stimulation Use for Parkinson's Disease in Ontario, Canada. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 642-655.	0.5	10
56	Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	9
57	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1087-1098.	2.8	46
58	Hypertension and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 166-170.	2.2	12
59	Recent developments in drug-induced movement disorders: a mixed picture. <i>Lancet Neurology</i> , The, 2019, 18, 880-890.	10.2	52
60	Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 34-39.	2.2	18
61	Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force. <i>Movement Disorders</i> , 2019, 34, 1602-1613.	3.9	23
62	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	2.8	29
63	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019, 66, 245-246.	2.2	0
64	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019, 29, 603-614.	2.5	10
65	Communication About OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners. <i>Frontiers in Neurology</i> , 2019, 10, 892.	2.4	12
66	The experience of off periods: Qualitative analysis of interviews with persons with Parkinson's and carepartners. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2019, 1, 31-36.	0.9	4
67	We are what we eat " editors' note on the role of diet in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1-1.	3.9	6
68	Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade. <i>Movement Disorders</i> , 2019, 34, 801-811.	3.9	116
69	Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews. <i>PLoS ONE</i> , 2019, 14, e0215384.	2.5	24
70	Reply to "Neuropathological progression of clinical Parkinson disease subtypes". <i>Nature Reviews Neurology</i> , 2019, 15, 361-362.	10.1	0
71	Concordance for Parkinson's disease in twins: A 20-year update. <i>Annals of Neurology</i> , 2019, 85, 600-605.	5.3	64
72	Clinical Parkinson disease subtyping does not predict pathology. <i>Nature Reviews Neurology</i> , 2019, 15, 189-190.	10.1	42

#	ARTICLE	IF	CITATIONS
73	Cognitive Complaints in Nondemented Parkinson's Disease Patients and Their Close Contacts do not Predict Worse Cognitive Outcome. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 147-153.	1.3	11
74	Risk of Parkinson's disease dementia related to level I MDS PD-MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	3.9	32
75	22q11.2 Deletion Syndrome—Associated Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 11-16.	1.5	22
76	Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. <i>Movement Disorders</i> , 2018, 33, 468-472.	3.9	14
77	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	3.9	2
78	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	3.9	12
79	A 21-Year Retrospective Study of the Toronto Western Hospital Deep Brain Stimulation Cohort. <i>Movement Disorders</i> , 2018, 33, 850-852.	3.9	4
80	Genotype-Phenotype Relations for the Parkinson's Disease Genes <i>Parkin</i> , <i>PINK1</i> , <i>DJ1</i> : MDSGene Systematic Review. <i>Movement Disorders</i> , 2018, 33, 730-741.	3.9	215
81	Initial cognitive changes in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 511-519.	3.9	41
82	Treatable inherited rare movement disorders. <i>Movement Disorders</i> , 2018, 33, 21-35.	3.9	79
83	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	3.9	138
84	Anti-inflammatory drug use and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 48, 89-92.	2.2	6
85	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	2.8	18
86	Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review. <i>Movement Disorders</i> , 2018, 33, 1857-1870.	3.9	120
87	Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	3.9	42
88	Antipsychotic Drug Dispensing in Older Adults With Parkinsonism. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 1244-1257.	1.2	4
89	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5164-E5173.	7.1	83
90	The genetic nomenclature of recessive cerebellar ataxias. <i>Movement Disorders</i> , 2018, 33, 1056-1076.	3.9	61

#	ARTICLE	IF	CITATIONS
91	Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. <i>Npj Parkinson's Disease</i> , 2018, 4, 19.	5.3	110
92	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	2.2	63
93	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	3.4	64
94	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.1	35
95	Brain tissue pulsatility is related to clinical features of Parkinson's disease. <i>NeuroImage: Clinical</i> , 2018, 20, 222-227.	2.7	5
96	Understanding, Impact, and Communication of "Off" Periods in Parkinson's Disease: A Scoping Review. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 461-470.	1.5	15
97	Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 793-802.	1.7	32
98	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	2.8	10
99	Antipsychotic Use and Physical Morbidity in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 697-705.	1.2	28
100	Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer. <i>World Journal of Urology</i> , 2017, 35, 1417-1423.	2.2	11
101	The financial burden of prescription drugs for neurological conditions in Canada: Results from the National Population Health Study of Neurological Conditions. <i>Health Policy</i> , 2017, 121, 389-396.	3.0	6
102	Mild cognitive impairment as a risk factor for Parkinson's disease dementia. <i>Movement Disorders</i> , 2017, 32, 1056-1065.	3.9	117
103	The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies. <i>Movement Disorders</i> , 2017, 32, 726-738.	3.9	48
104	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017, 140, 1371-1383.	7.6	41
105	What would Dames Parkinson think today? : Measuring Health-Related Quality of Life. <i>Movement Disorders</i> , 2017, 32, 364-365.	3.9	0
106	Understanding falls in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 75-81.	2.2	15
107	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. <i>Movement Disorders</i> , 2017, 32, 1432-1438.	3.9	126
108	Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. <i>Journal of Parkinson's Disease</i> , 2017, 7, 193-202.	2.8	92

#	ARTICLE	IF	CITATIONS
109	Nonmotor Signs in Genetic Forms of Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 129-178.	2.0	31
110	Inflammatory profile in LRRK2-associated prodromal and clinical PD. <i>Journal of Neuroinflammation</i> , 2016, 13, 122.	7.2	57
111	Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. <i>Movement Disorders</i> , 2016, 31, 644-652.	3.9	53
112	Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1192-1202.	3.9	102
113	Launching the movement disorders society genetic mutation database (MDSGene). <i>Movement Disorders</i> , 2016, 31, 607-609.	3.9	54
114	Nonmotor features of Parkinson's disease subtypes. <i>Movement Disorders</i> , 2016, 31, 1095-1102.	3.9	254
115	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. <i>Movement Disorders</i> , 2016, 31, 436-457.	3.9	228
116	Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. <i>Movement Disorders</i> , 2016, 31, 906-914.	3.9	29
117	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016, 31, 1243-1247.	3.9	48
118	The Danger of Not Treating Parkinson Disease Psychosis—Reply. <i>JAMA Neurology</i> , 2016, 73, 1156.	9.0	3
119	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 461-472.	2.4	35
120	Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!. <i>Movement Disorders</i> , 2016, 31, 1760-1762.	3.9	1
121	Nonmotor series. <i>Movement Disorders</i> , 2016, 31, 1079-1079.	3.9	0
122	Lithium Use in Older Adults is Associated with Increased Prescribing of Parkinson Medications. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 301-309.	1.2	31
123	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 535.	9.0	136
124	Sequence of electrode implantation and outcome of deep brain stimulation for Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 859-863.	1.9	20
125	Knowledge of Parkinson's Disease in a Multiethnic Urban Asian Setting. <i>Journal of Parkinson's Disease</i> , 2015, 5, 865-879.	2.8	16
126	Independent application of montreal cognitive assessment/mini-mental state examination conversion. <i>Movement Disorders</i> , 2015, 30, 1710-1711.	3.9	7



#	ARTICLE	IF	CITATIONS
127	Subtypes of Parkinson's disease. <i>Current Opinion in Neurology</i> , 2015, 28, 382-386.	3.6	47
128	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	9.0	272
129	<i>Helicobacter pylori</i> infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 221-225.	2.2	107
130	Telemedicine in Parkinson's disease: A patient perspective at a tertiary care centre. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 525-528.	2.2	50
131	The relevance of pre-motor symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1205-1217.	2.8	29
132	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014, 16, 644-645.	2.4	7
133	Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada. <i>Drugs and Aging</i> , 2014, 31, 805-813.	2.7	6
134	The tools of the trade: A state of the art "How to Assess Cognition" in the patient with Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 584-596.	3.9	52
135	Small intestinal bacterial overgrowth in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 535-540.	2.2	217
136	Systematic Review of the Risk of Parkinson's Disease After Mild Traumatic Brain Injury: Results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, S238-S244.	0.9	68
137	Dietary fat intake, pesticide use, and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 82-87.	2.2	108
138	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , 2014, 384, 1164-1166.	13.7	17
139	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 222-225.	2.2	25
140	Systematic Review of the Risk of Dementia and Chronic Cognitive Impairment After Mild Traumatic Brain Injury: Results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, S245-S256.	0.9	99
141	The complexities of hormonal influences and risk of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 845-848.	3.9	16
142	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 608-612.	2.2	5
143	Measuring mild cognitive impairment in patients with Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 626-633.	3.9	120
144	Parkinson's disease subtypes: lost in translation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 409-415.	1.9	181

#	ARTICLE	IF	CITATIONS
145	Fixing the broken system of genetic locus symbols. <i>Neurology</i> , 2012, 78, 1016-1024.	1.1	70
146	Atypical Antipsychotic Use and Parkinsonism in Dementia: Effects of Drug, Dose, and Sex. <i>American Journal of Geriatric Pharmacotherapy</i> , 2012, 10, 381-389.e3.	3.0	11
147	Antipsychotics and Mortality in Parkinsonism. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 149-158.	1.2	29
148	The pill questionnaire in a nondemented Parkinson's disease population. <i>Movement Disorders</i> , 2012, 27, 1308-1311.	3.9	15
149	Dihydropyridine calcium channel blockers and the progression of parkinsonism. <i>Annals of Neurology</i> , 2012, 71, 362-369.	5.3	55
150	Piecing together the puzzle of progression and mortality in Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 264-266.	2.4	2
151	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	3.9	20
152	Reply: Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for long-term clinical trials. <i>Movement Disorders</i> , 2011, 26, 1371-1371.	3.9	0
153	Cochrane Review: Pimozide for tics in Tourette's syndrome. <i>Evidence-Based Child Health: A Cochrane Review Journal</i> , 2011, 6, 240-254.	2.0	0
154	Genetics Meets Environment: Evaluating Gene-Environment Interactions in Neurologic Diseases. <i>Seminars in Neurology</i> , 2011, 31, 553-562.	1.4	8
155	LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.	3.1	9
156	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009, 24, 2370-2378.	3.9	11
157	Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. <i>Movement Disorders</i> , 2008, 23, 653-659.	3.9	122
158	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2008, 7, 583-590.	10.2	1,340
159	Invited Article: Changing concepts in Parkinson disease. <i>Neurology</i> , 2008, 70, 1996-2003.	1.1	73
160	Antipsychotic use in older adults with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 319-323.	3.9	26
161	Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. <i>Movement Disorders</i> , 2004, 19, 22-28.	3.9	89
162	Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 985-993.	2.8	16

#	ARTICLE	IF	CITATIONS
163	Predicting Motor Decline and Disability in Parkinson Disease. Archives of Neurology, 2002, 59, 1724.	4.5	179
164	69-Year-old man with gait disturbance and parkinsonism. Movement Disorders, 2001, 16, 548-561.	3.9	1
165	Cervical Myelopathy Caused by Hypoplasia of the Atlas: Two Case Reports and Review of the Literature. Neurosurgery, 1998, 43, 629-633.	1.1	86